Wedbush Morgan upgrades Halozyme Therapeutics, Inc. (Nasdaq: HALO) from Neutral to Outperform. Price target increased from $7 to $10.

Wedbush ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE